Smart Vision Labs announced that clinical testing results on its SVOne autorefractor were comparable with subjective refraction and an office-based autorefractor when measuring refractive error under cycloplegic and non-cycloplegic conditions in young adults with normal vision, according to a press release.
The results will be published in the December issue of Optometry and Vision Science, the company said in a press release.
“The smartphone-based SVOne literally puts the power to examine vision in the hands of the clinician,” researcher Kenneth J. Ciuffreda, OD, PhD, FAAO, FCOVD-A, FARVO, said in the announcement. “This can facilitate the ability to check vision both inside and outside the clinical setting, thereby addressing the need to expand the availability, efficiency and accessibility of vision exams.”
The FDA Class 1 exempt medical device uses iPhone’s computing power and camera to perform wavefront aberrometry and obtain the patient’s refractive error, according to Smart Vision Labs.
In the clinical testing of 50 patients, the refractive findings from SVOne were highly correlated to those measured using subjective refraction, the company said.
“The SVOne changes the autorefraction paradigm...What SVOne and other autorefractors offer is an objective measure of refractive error, which is thus less prone to investigator bias or error,” according to Bernard Spier, MD, FAAO, who has used the application in the U.S. and overseas.
“What makes SVOne different, however, is its accessibility and affordability compared with an office-based platform,” he said.
Disclosures: Ciuffreda and Spier report no direct financial interest in Smart Vision Labs.